The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.
 
J. Thaddeus Beck
Research Funding - AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); DSi (Inst); Lilly (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Dale Randall Shepard
Honoraria - Deciphera
Consulting or Advisory Role - AADi; Deciphera; Sanofi; SpringWorks Therapeutics
Research Funding - aadi (Inst); Abbisko Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cogent Biosciences (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Deciphera (Inst); Genentech/Roche (Inst); Harpoon therapeutics (Inst); InhibRx (Inst); Kinnate Biopharma (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Novartis (Inst); Pfizer (Inst); Pionyr (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Shanghai Miracogen Inc. (Inst); tempus (Inst); VBL Therapeutics (Inst)
 
Olivier Dumas
No Relationships to Disclose
 
Rossanna C. Pezo
Honoraria - Merck; Novartis Canada Pharmaceuticals Inc; Pfizer/EMD Serono
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Lilly; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche; Sanofi
Speakers' Bureau - Novartis Canada Pharmaceuticals Inc
Research Funding - Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
April A. N. Rose
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; EMD Serono
Research Funding - AstraZeneca Canada (Inst); Canada Foundation for Innovation; Canadian Cancer Society; Canadian Institutes of Health Research (CIHR); Conquer Cancer Foundation; Jewish General Hospital Foundation; Merck (Inst); Pfizer (Inst); Seagen (Inst); TransMedTech Institute
 
Michael Ong
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer/EMD Serono; Sanofi
Research Funding - AstraZeneca
 
Ramy R. Saleh
No Relationships to Disclose
 
Fabio Iwamoto
Stock and Other Ownership Interests - Praesidia Biotherapeutics
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Clearview Cancer Institute; Gennao Bio; Guidepoint Global; KIYATEC; Massive Bio; Medtronic; Merck; MimiVax; Novocure; PPD; Praesidia Biotherapeutics; Regeneron; Tocagen; xCures
Speakers' Bureau - Prime Oncology
Research Funding - ABM; ABM; AstraZeneca; Bristol-Myers Squibb; Celldex; FORMA Therapeutics; Merck; Northwest Biotherapeutics; Novocure; Pfizer; Sapience Therapeutics; tocagen
Travel, Accommodations, Expenses - Oncoceutics
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics
 
Juliette Gray
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Lance Wollenberg
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Arnab Maity
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Keren Sturtz
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer